리포트 공감능력📂

Forwarded from 텐렙

#알테오젠 #머크 #엄본좌 #엄민용

Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference

https://seekingalpha.com/article/4676086-merck-and-co-inc-mrk-td-cowen-44th-annual-healthcare-conference-transcript

키트루다SC 관련 내용만 정리했습니다. 머크 전체 질의응답이 총 30분으로 길진 않았지만 마지막에 의미심장한 답변이 있었습니다.

피하투여 시 약효 지속력이 높아져 전체생존률 증가나 다른 쪽에서 이점이 있을 것으로 기대한다고 답변합니다.

피하로 바꿨을 뿐인데 환자투약 편의성 외에 유효성이 증가한다?! 아직3상 결과가 발표된 것은 아니지만 이번 답변으로 기대해볼 수 있겠습니다.

Steve Scala

Now I guess, saturation could occur either because the markets are truly saturated or KEYTRUDA is giving no opportunity to grow. So, what is the outlook for KEYTRUDA in O-U.S. markets, both in metastatic and early-stage settings?

키트루다는 이미 시장이 포화상태? 미국 외 국가에서 키트루다 시장 전략은? 전이암과 초기암에서 측면에서 아웃룩 어떤가?

Joe Romanelli

So I think at a very high level, we continue to see KEYTRUDA as an opportunity for growth in 2024.

매우 높은 수준으로 2024년 성장을 이어갈 것으로 기대한다.

If you look at our business internationally, 80% of the business is metastatic. Within that 80%, roughly 50% of that is in lung. And if I look, particularly in Europe, we have around 60% to 80% market share across the markets.

전이 암 비중이 80%, 초기 암 20% 비중이고 전이 암 80% 중 50%가 폐암 비중, 우린 유럽에서 60-80% 시장 점유율 가지고 있음

In the earlier stage setting, we've done a really nice job, it's about 20%.
…
But for us, last year, if we look at triple-negative breast was roughly 50% of our growth. And I would say probably the best opportunity we have because -- we talk a lot about screening. Triple-negative breast, there's very robust screening programs in the world. So women are identified their screen, they're diagnosed, and we can get them on treatment early, which is fantastic.

Joe Romanelli

So, I would just say metastatic, we anticipate metastatic will continue to grow, but the majority of our growth will come from the early-stage setting.

작년 삼중음성유방암이 50% 성장함, 삼중음성유방암을 일찍 치료해줄 수 있는 굉장한 성과 보유 중, 전이 암 시장도 성장하겠지만 우리의 성장의 주력은 초기암 세팅일 것

Steve Scala

Of course, Merck is working on subcutaneous formulation, and we, analysts, kind of look at it and say that's interesting and think about the U.S. market, but couldn't it really be a major opportunity O-U.S., where they don't have quite the same facilities we have in the U.S. for infusing drugs. So, what is the opportunity for subcu KEYTRUDA outside the U.S.?

키트루다를 피하로 주사하는 것이 미국 외 국가에서의 판매를 위한 준비는 안되어있는 것인지? 미국 외 국가에서 키트루다SC 전략은?

Joe Romanelli

We're watching closely. We're seeing, obviously, Tecentriq is the first one to have that conversion. What we're seeing, it depends on the market. In places like the U.K., you're going to see probably a faster adoption. And what we're seeing today is the majority of that adoption is having within the product itself.
…
especially as we transition from the metastatic business to the early-stage business to help patients kind of improve that process. These are younger patients.

시장에 첫 출시된 티쎈트릭이 영국에거 굉장히 빠르게 전환되고 있고 로슈 자체적으로 SC제품으로 전환시키고 있음

전이암부터 초기암까지 전환될 것으로 예상되며 환자의 복약편의성을 개선시킬 것

These are generally patients that want to have treatment outside of the hospital. So, if we can do that with a subcu formulation, I think that's kind of -- it will improve care will improve the ability for the hospitals to manage for patients who are going in for IV. And certainly,

I think, hopefully, from a duration perspective, keep patients on these assets a longer period of time to make sure they reap the benefits of OS and others.

이 환자들은 병원 밖에서 맞는 것을 더 선호하는데 키트루다SC가 할 수 있을 것

혈관주사를 투약 중이 환자들도 병원에서 관리하는 능력을 개선하는 것에 도움을 줄 수 있을 것

희망하건데 SC는 약효가 더 지속되기 때문에 전체생존률(OS)이나 다른 것에서도 이점이 있을 것으로 기대한다.

Seeking Alpha

Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript)

Merck & Co., Inc. (NYSE:NYSE:MRK) TD Cowen 44th Annual Healthcare Conference March 5, 2024 1:30 PM ETCompany ParticipantsJoe Romanelli - President of...

170 views00:05